|
MASTL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.90403248723214E-13 |
| Normal-vs-Stage2 |
8.89340046050791E-10 |
| Normal-vs-Stage3 |
3.29847260616134E-13 |
| Normal-vs-Stage4 |
1.40950029425824E-10 |
| Stage1-vs-Stage2 |
2.267400E-01 |
| Stage1-vs-Stage3 |
7.490400E-02 |
| Stage1-vs-Stage4 |
2.074600E-01 |
| Stage2-vs-Stage3 |
9.092400E-01 |
| Stage2-vs-Stage4 |
8.705800E-01 |
| Stage3-vs-Stage4 |
7.480400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
1.394410E-02 |
| Normal-vs-Asian |
3.58613139184172E-12 |
| Caucasian-vs-AfricanAmerican |
8.120400E-03 |
| Caucasian-vs-Asian |
8.384100E-02 |
| AfricanAmerican-vs-Asian |
7.437500E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.56630264314117E-11 |
| Normal-vs-Female |
1.63336011382853E-12 |
| Male-vs-Female |
2.675600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.27350027692808E-10 |
| Normal-vs-Age(41-60Yrs) |
1.99840144432528E-15 |
| Normal-vs-Age(61-80Yrs) |
2.758204775688E-11 |
| Normal-vs-Age(81-100Yrs) |
6.214800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.698000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.221700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.823600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.561600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.813200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.830400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.926000E-02 |
| Classical-VS-Follicular |
2.872400E-01 |
| Classical-VS-Other |
4.309200E-01 |
| Classical-VS-Normal |
2.87250001562711E-09 |
| Tall-VS-Follicular |
4.033200E-01 |
| Tall-VS-Other |
9.264400E-01 |
| Tall-VS-Normal |
1.99159999603182E-09 |
| Follicular-VS-Other |
7.091800E-01 |
| Follicular-VS-Normal |
3.8837000282399E-10 |
| Other-VS-Normal |
1.779090E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.96109836439973E-14 |
| Normal-vs-N1 |
2.73879996459669E-09 |
| N0-vs-N1 |
8.579200E-01 |
|
|
